insights_auto
FARN میں کمی کیوں آئی؟ 4.11%?
گہرائی سے تحقیق کریںchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 35.00
arrow_downward
-4.11%(-1.50) 1 دن
9 اکتوبر, 4:30:00 PM GMT +1 · GBX
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoFARN کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
GBX 35.00
اعلی
GBX 38.00
کم
GBX 35.00
مارکیٹ کی سرمایہ کاری
7.40 کروڑ
اوسط والیوم
45.22 ہزار
والیوم
15.60 ہزار
52 ہفتے میں اعلی
GBX 193.58
52 ہفتے کا کم
GBX 34.00
EPS
-GBX 0.10
بقایہ شیئرز
3.10 کروڑ
ملازمین کی تعداد
36
کھولیں
GBX 35.00
اعلی
GBX 38.00
کم
GBX 35.00
مارکیٹ کی سرمایہ کاری
7.40 کروڑ
اوسط والیوم
45.22 ہزار
والیوم
15.60 ہزار
52 ہفتے میں اعلی
GBX 193.58
52 ہفتے کا کم
GBX 34.00
EPS
-GBX 0.10
بقایہ شیئرز
3.10 کروڑ
ملازمین کی تعداد
36
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
Bloomberg.com
·
1 گھنٹہ پہلے
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Barchart.com
·
1 گھنٹہ پہلے
The S&P 500 Is Near Record Highs. So Why Does Your Portfolio Feel Like a Bear Market?
Simply Wall Street
·
1 گھنٹہ پہلے
Palomar Holdings (PLMR) Could Be 20% Undervalued As Rating Strength Holds
Yahoo Finance
·
4 گھنٹے پہلے
Beyond S&P 500 Index Funds: Here's the 1 Sector I'd Buy First as a New Investor
پروفائل
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy کے بارے میں